Medincell to Present Data Showing Enhanced Potential of Tumor-Targeting Monoclonal Antibody in Melanoma Using BEPO® Technology
2024年7月2日 - 12:45AM
ビジネスワイヤ(英語)
Regulatory News:
Medincell (Paris:MEDCL) will provide an overview of some of
its R&D programs related to its cutting-edge Long-Acting
Injectable technologies through several presentations and posters
at the CRS 2024 conference, from July 8 to 12 in Bologna, Italy,
including:
- Oncology field: Presentation of in vivo data showing the
improved immunomodulatory potential of a tumor-targeting monoclonal
antibody in melanoma using BEPO® technology for peritumoral
administration.
- Introduction to BEPO® STAR: Overview of the novel
Medincell’s proprietary Long-Acting Injectable technology designed
to enhance controlled delivery across a broader range of drugs and
therapeutic areas.
- Medincell proprietary in vitro release tool:
Presentation of an innovative in vitro lab tool designed to
accelerate formulation activities and preclinical candidates
selection.
Adolfo Lopez-Noriega, Head of R&D at Medincell, said:
"Innovation is our cornerstone, driving our advanced technologies
and their groundbreaking applications. Our world-class R&D team
is dedicated to continuously pushing the boundaries, enhancing our
technology's reach, and ensuring our position at the forefront of
controlled and targeted drug delivery. Our advancements aim to
deliver superior therapeutic options through systemic or local
delivery in areas where we can make a significant impact, such as
psychiatry, oncology, obesity, or pain management. Attending CRS
allows us to share our recent achievements and underscores our
commitment to forging strong partnerships with both academia and
pharmaceutical companies."
Organized by the Controlled Release Society, the CRS Annual
Meeting is a prominent conference in the field of controlled
release science and technology. It covers a wide range of topics,
including drug delivery systems, biomaterials, nanotechnology,
polymers, and regulatory aspects of controlled release products.
It’s a major event for all academics and pharmaceutical industry
professionals involved in the development and application of
controlled release technologies.
Event website: https://2024crsannualmeeting.eventscribe.net/
About Medincell
Medincell is a clinical- and commercial-stage biopharmaceutical
licensing company developing long-acting injectable drugs in many
therapeutic areas. Our innovative treatments aim to guarantee
compliance with medical prescriptions, to improve the effectiveness
and accessibility of medicines, and to reduce their environmental
footprint. They combine active pharmaceutical ingredients with our
proprietary BEPO® technology which controls the delivery of a drug
at a therapeutic level for several days, weeks or months from the
subcutaneous or local injection of a simple deposit of a few
millimeters, entirely bioresorbable. The first treatment based on
BEPO® technology, intended for the treatment of schizophrenia, was
approved by the FDA in April 2023, and is now distributed in the
United States by Teva under the name UZEDY® (BEPO® technology is
licensed to Teva under the name SteadyTeq™). We collaborate with
leading pharmaceutical companies and foundations to improve global
health through new treatment options. Based in Montpellier,
Medincell currently employs more than 140 people representing more
than 25 different nationalities. UZEDY® and SteadyTeq™ are
registered trademarks of Teva Pharmaceuticals.
www.medincell.com
This press release may contain forward-looking statements,
particularly concerning the progress of the Company's clinical
trials. Although the Company considers that its forecasts are based
on reasonable assumptions, any statements other than statements of
historical fact that may be contained in this press release
relating to future events are subject to change without notice, to
factors beyond the Company's control and to the Company's financial
capabilities.
These statements may include, but are not limited to, any
statements beginning with, followed by or including words or
expressions such as "objective", "believe", "expect", "aim",
"intend", "may", "anticipate", "estimate", "plan", "project",
"will", "may", "probably", "should", "could" and other words or
expressions of similar meaning or used in the negative.
Forward-looking statements are subject to inherent risks and
uncertainties beyond the Company's control which may cause actual
results, performance or achievements of the Company to differ
materially from those anticipated or implied by such
statements.
A list and description of such risks, hazards and uncertainties
can be found in the documents filed by the Company with the
Autorité des Marchés Financiers (AMF) pursuant to its regulatory
obligations, including in the Company's document de base,
registered with the AMF on September 4, 2018 under number I.
18-062, as well as in documents and reports to be published
subsequently by the Company. Furthermore, these forward-looking
statements only apply as of the date of this press release. Readers
are cautioned not to place undue reliance on these forward-looking
statements. Except as required by law, the Company undertakes no
obligation to publicly update these forward-looking statements, nor
to update the reasons why actual results may differ materially from
those anticipated in the forward-looking statements, even if new
information becomes available. The Company's updating of one or
more forward-looking statements does not imply that it will or will
not update these or any other forward-looking statements.
This press release is published for information purposes only.
The information contained herein does not constitute an offer to
sell or a solicitation of an offer to buy or subscribe for
securities of the Company in any jurisdiction whatsoever,
particularly in France. Similarly, this press release does not
constitute investment advice and should not be treated as such. It
is not intended to address the investment objectives, financial
situation or specific needs of any particular recipient. It should
not be relied upon as a substitute for the exercise of your own
judgement. All opinions expressed in this document are subject to
change without notice. The distribution of this press release may
be restricted by law in certain jurisdictions. Persons into whose
possession this press release comes are required to inform
themselves about and to observe any such restrictions.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240701450908/en/
David Heuzé - Head of Corporate and Financial Communications,
and ESG david.heuze@medincell.com / +33 (0)6 83 25 21 86
Grace Kim - Head of US Financial Strategy and IR
grace.kim@medincell.com / +1 (646) 991-4023
Investors Relations France Louis-Victor
Delouvrier/Alban Dufumier medincell@newcap.eu / +33 (0)1 44 71
94 94
Media Relations Nicolas Mérigeau
medincell@newcap.eu / +33 (0)1 44 71 94 94
Medincell (EU:MEDCL)
過去 株価チャート
から 6 2024 まで 7 2024
Medincell (EU:MEDCL)
過去 株価チャート
から 7 2023 まで 7 2024